Search results for " response rate"

showing 6 items of 6 documents

A Comparative Facebook Content Analysis between Romanian and Western European Airline Carriers

2014

This research aims to investigate the different social media strategies adopted by the airline companies from two European regions. In the attempt to land more customers on their social media runway, drive more sales from social media content, increase customer satisfaction through a high response rate or increase their brand awareness, the airlines combine creativity and high-quality ideas to better promote their products and services to customers all around the globe. The paper analyses the content (number of fans, posts, number of likes, the dynamics of comments, response rate) on the Facebook pages of Tarom, Blue Air, Wizz Air, Lufthansa, Austrian Airlines, KLM International and Air Eur…

Lufthansasocial networksresponse rateTaromFacebookAir Europa.lcsh:Marketing. Distribution of productscustomer satisfactioncustomer loyaltysocial mediaKLMBlue Airjel:M11jel:M30jel:M31customer satisfaction customer loyalty social media social networks airline companies response rate Facebook Tarom Blue Air Wizz Air Lufthansa Austrian Airlines KLM Air EuropaAustrian Airlineslcsh:HF5410-5417.5airline companiesWizz AirExpert Journal of Marketing
researchProduct

Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.

2012

6584 Background: In Study 406, the anti-CD20 monoclonal antibody ofatumumab (ofa), given as monotherapy over 6 months, showed 47% overall response rate (ORR) in patients (pts) with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab (FA-ref), or to fludarabine with bulky (>5cm) lymphadenopathy (BF-ref). The effects of ofa retreatment (retx) and maintenance (mt) are unknown. Methods: Pts who responded to ofa and then progressed or had stable disease (SD) in Study 406, were offered retx in Study 416 (NCT00802737; GSK/Genmab) with ofa 1 x 300 mg + 7 x 2000 mg weekly followed by mt with ofa 2000 mg monthly for up to 2 years (if SD or better). Primary endpoint was OR…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classbusiness.industryMonoclonal antibodyOfatumumabchemistry.chemical_compoundOverall response rateOncologychemistryFludarabine refractoryInternal medicinemedicineIn patientbusiness
researchProduct

455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in …

2021

Oncologymedicine.medical_specialtyColorectal cancerbusiness.industryConcordanceFirst lineHematologymedicine.diseaseOverall response rateOncologyCell-free fetal DNAInternal medicineCohortmedicineMutational statusbusinessAnnals of Oncology
researchProduct

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

2015

Abstract: Background: Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods: Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (ly-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities. Results: Six eligible trials (741 patients) were selected. Pooled analysis showed a significan…

Oncologymedicine.medical_specialtyLung NeoplasmsPhase iii trialsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPopulationSettore MED/21 - Chirurgia ToracicaNSCLClaw.inventionSingle agentOverall response rateRandomized controlled trialPerformance statuNSCLC; Chemotherapy; Performance status; Platinum; Doublet; Single agentlawCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIntensive care medicineeducationRandomized Controlled Trials as TopicPlatinumChemotherapyeducation.field_of_studyPerformance statusbusiness.industryHematologySurvival RateOncologyMeta-analysisDoubletNon small cellHuman medicinePerformance statusbusiness
researchProduct

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELI…

2013

8507 Background: Therapies approved in US for R/R PTCL have overall response rates (ORR) of 25%-27%. The need for new therapies persists. BELIEF is a pivotal, single-arm study of belinostat in patients with R/R PTCL after failure of ≥1 prior systemic therapies. Methods: Entry criteria were measurable PTCL, platelets ≥ 50,000/µL, no prior HDACi therapy, and adequate organ function. PTCL was confirmed by central pathology review (CPRG). Belinostat 30 min IV infusion at 1000 mg/m2was administered on days 1–5 of a 3 week cycle until progression or unacceptable toxicity. Tumor response was assessed by Cheson 2007 criteria. The primary endpoint was ORR. Results: Patients with R/R PTCL (N=129, 53…

Refractory Peripheral T-cell LymphomaCancer Researchmedicine.drug_classbusiness.industryHistone deacetylase inhibitorchemistry.chemical_compoundOverall response rateOncologychemistryImmunologymedicineCancer researchbusinessBelinostatJournal of Clinical Oncology
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct